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Chronic intervillositis of unknown etiology (CIUE) is a poorly understood, relatively rare condition
characterized histologically by the intervillous infiltration of mononuclear cells in the placenta. Clini-
cally, CIUE is associated with poor pregnancy outcome (e.g., impaired fetal growth, preterm birth, fetal
death) and high risk of recurrence in subsequent pregnancies. Because CIUE is not defined consistently,
it is essential to clearly define this condition. We therefore review the published definitions of CIUE. In
addition, we provide an overview of the reviewed histopathological and maternal characteristics, ob-
stetric features, and pregnancy outcomes. Medical publication databases were searched for articles
published through February 2017. Eighteen studies were included in our systematic review. The sole
inclusion criterion used in all studies was the presence of intervillous infiltrates. Overall, CIUE was
characterized by adverse pregnancy outcome. Miscarriage occurred in 24% of cases, with approximately
half of these miscarriages defined as late. Impaired growth was commonly observed, 32.4% of preg-
nancies reached term, and the live birth rate was 54.9%. The high recurrence rate (25.1%) of the inter-
villous infiltrates in subsequent pregnancies underscores the clinical relevance of CIUE, the need for
increased awareness among pathologists and clinicians, and the need for further research. Criteria for
the diagnosis of CIUE are proposed and a Delphi study could be used to resolve any controversy
regarding these criteria. Future studies should be designed to characterize the full clinical spectrum of
CIUE.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Chronic intervillositis of unknown etiology (CIUE) is a poorly
understood, relatively rare condition first described in 1987 by
Labarrere and Mullen as massive chronic intervillositis. They
defined massive chronic intervillositis as a histopathological
finding characterized by the intervillous infiltration of mono-
nuclear cells in the placenta, fibrin deposits and trophoblast ne-
crosis [1]. CIUE appears to be associated with poor perinatal
outcome, including miscarriage, reduced fetal growth, and fetal
death [2,3]. In addition, CIUE has a 4e100% chance of recurrence in
a subsequent pregnancy [2e6]. The incidence of CIUE in the second
and third trimester is 6 out of 10,000 pregnancies, and CIUE-related
miscarriage occurs in 44 out of 1000 pregnancies inwhich the fetus
has a normal karyotype [4].Nomenclature
In this review is referred to a condition that encompasses
the presence of chronic intervillositis accompanied by
pregnancy complications, a high recurrence risk, and the
absence of a known (infectious) cause. Since these chronic
intervillous infiltrates were first described as massive
chronic intervillositis by Labarrere and Mullen, a variety of
terms have been used to describe this condition, including
“chronic intervillositis of unknown etiology”, “chronic
intervillositis”, “chronic histiocytic intervillositis of un-
known etiology”, “chronic histiocytic intervillositis”,
“massive histiocytic chronic intervillositis”, “massive peri-
villous histiocytosis”, “intervillitis”, and “massive chronic
intervillositis” [8]. It is important to distinguish between
chronic intervillositis referring to a histologic placenta
lesion irrespective of the cause, and the specific condition
we define. The term “chronic intervillositis of unknown
etiology (CIUE)” should be used in further research on the
condition we define in this systematic review.Immunological and/or coagulation disturbances may play a role
in the pathophysiology of CIUE. For example, the occurrence of
intervillous infiltrates with focal villitis [2,5] and the presence of
C4d deposits in CIUE are indicative of an immunological distur-
bance [7]. In addition, increased placental expression of intercel-
lular adhesion molecule-1 [8] and the presence of CIUE-specific cellinfiltrates [9] suggest an immunopathological component. More-
over, Reus et al. recently suggested that the pathophysiology of
CIUE might be based on a HLA mismatch between the “donor”
(fetal-paternal antigens) and the “recipient” (the mother); this
suggestion was based on observations of mixed lymphocyte re-
actions and the prevalence of cytotoxic T lymphocyte precursors
cells [10]. Furthermore, the presence of CIUE in cases with neonatal
alloimmune thrombocytopenia, which is caused by maternal an-
tibodies against paternally derived human platelet antigens, may
suggest a process comparable to chronic rejection [11,12]. The
presence of perivillous fibrin deposits in CIUE suggest coagulative
disturbances, this likely is due to an immune-mediated process
[4,13]. Interestingly, chronic intervillositis is also observed in the
placentas of women with malaria and/or acute cytomegalovirus
infection [14,15]. Although reduced fetal growth and preterm birth
are also observed in pregnancies complicated by malaria, perinatal
mortality is not frequently observed in these pregnancies [14]. The
co-occurrence of chronic intervillositis andmalaria has given rise to
the hypothesis that an underlying, not yet identified, infection may
be associated with CIUE.
Given that CIUE is associated with a high risk of recurrence and
with adverse pregnancy outcome [2e6], prevention is the best
approach. A few studies reported positive effects of treatment with
aspirin, heparin, prednisolone, and/or corticosteroids in various
dosages and combinations [2e4,16,17]. A meta-analysis by Contro
et al. revealed that the reported live birth rate does not significantly
improve with treatment [5]. However, more recent studies suggest
a different combination therapy for CIUE, which was beneficial in
few cases [18,19]. This combination treatment was not reviewed in
the meta-analysis [5]. Extensive national or international studies
including as many patients as possible are needed to elucidate the
etiology of CIUE and to investigate therapeutic approaches.
Since different terms are used over the time to describe CIUE [8],
it is likely that different definitions, inclusion criteria and exclusion
criteria are used in various studies. Therefore, developing a clear
definition of CIUE is an essential first step towards comparable
study results and understanding the etiology of CIUE.
Our primary objective is to review the published definitions of
CIUE, as well as the inclusion and/or exclusion criteria used in all
studies regarding CIUE published from 1987 through February
2017. In addition, we provide an overview of the investigated his-
topathological parameters and immunological characteristics of
the cellular infiltrates, and we review the clinical features, obstetric






Review (55); book chapter(8); 
not relevant (96)  
Documented infec ons: malaria (97); 
other (34)
Not associated with chronic intervillosi s:
villi s (14); fibrin deposits (8) 
31 Mee ng abstracts (16); no available full text (1); case reports (13); cases from another study (1)
18
Fig. 1. Flowchart of the selection of publications included in this systematic review.
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2. Methods
2.1. Search methods
The following databases were searched for articles regarding
CIUE published from 1987 through February 2017: PubMed,
Embase, Web of Science, Emcare, Academic Search Premier, Sci-
enceDirect, Wiley-Blackwell, LLW, Highwire, and Google Scholar.
Each database was searched using the following terms: “massive
chronic intervillositis”, “chronic histiocytic intervillositis”, “inter-
villositis”, “perivillous histiocytosis”, and “intervillites”. The literature
search was performed by authors MB and JS. Complete details
regarding the search strategy details are available in Appendix A.
2.2. Selection of studies
Potentially relevant studies were reviewed independently by
authors MB and RT by scanning the article's title and abstract. All
peer-reviewed publications regarding histologically confirmed
cases of CIUE were included. We excluded non-observational
studies, reports of an intervillous infiltrate due to documented
infection, reports of other forms of villitis, case reports, and studies
with no full text available. Any disagreement regarding including a
study was resolved by consensus between authors MB and RT. The
references were checked in the included studies, and citation
tracking was performed.
2.3. Patient characteristics
Maternal age and gestational age were obtained from the pa-
tient data provided in each study and are reported as the mean,
standard deviation, and range. Gravidity and parity were also ob-
tained and were reported as median and range. In the event that
data were not published per patient, we used the reported
outcomes.
2.4. Pregnancy outcome
We collected the following data: the number of early and/or late
miscarriage, growth restriction, preterm births, stillbirths, perinatal
mortality, and the recurrence of CIUE in subsequent pregnancies.
Miscarriage was defined as the spontaneous loss of pregnancy
within the first 22 weeks of gestation [20]. Early and late mis-
carriages were defined as miscarriage that occurred at 12 weeks
of gestation and 12e22 weeks of gestation, respectively. Intra-
uterine growth restrictionwas defined as an estimated fetal weight
in the bottom 10th percentile for gestational age, and small for
gestational age was defined as a birth weight in the bottom 10th
percentile for the corresponding gestational age [21]. One study in a
Hispanic population did not determine growth based on gestational
age; we therefore determined these data using the appropriate
reference curves for this population [22]. A term pregnancy was
defined as birth 37 weeks, and preterm birth was defined as birth
<37 weeks of gestation. In approximately 50% of early miscarriages,
the fetus has a chromosomal abnormality [23]. However, cases of
CIUE in a study group of earlymiscarriages have been reported to be
karyotypically normal [24]. Maternal factors, such as coagulation
abnormalities, are more predominant in late miscarriages [25].
Since both, early and late miscarriages, might have a different eti-
ology, also in the context of CIUE, the proportions of term births
were calculated with and without early miscarriages [26]. World-
wide, the definition used for stillbirth varies [27]. For our purposes,
stillbirth was defined as pregnancy loss after 22 weeks of gestation[20]. A stillbirth event at term was considered as a pregnancy that
reached term. Perinatal mortality refers to both stillbirths and
neonatal deaths within the first postnatal week. We defined preg-
nancies resulting in a living child as the total number of pregnancies
with gestational age 12 weeks minus the number of pregnancies
that resulted in late miscarriage, stillbirth, or perinatal death. Cases
with missing data were excluded separately for each outcome.
3. Results
3.1. Selected studies
Our literature search revealed 361 unique publications. Fig. 1
shows a flowchart of the inclusion and exclusion of these publica-
tions. First, 312 publications were excluded based on the title and/
or abstract. Thirty-one of the remaining 49 publications were
excluded for the following reasons: 16 were meeting abstracts, 13
were case reports that included fewer than three cases, and the full
text was not available for one publication. Furthermore, one addi-
tional publication [28] was excluded because these cases were
already included in two other publications [29,30]. Reference
checking and citation tracking did not yield any new publications.
Thus, a total of 18 publications met our criteria and were included
in our systematic review [1e3,6e10,16e18,29e35]. These 18 pub-
lications reported a total of 291 women, including 350 pregnancies
with either an intervillous infiltrate in the placenta diagnosed as
CIUE or comparable lesions that were given a different name, e.g.
massive chronic intervillositis, chronic intervillositis, chronic his-
tiocytic intervillositis, chronic intervillitis or chronic histiocytic
intervillositis of unknown etiology. The publications included in
this review are summarized in Table 1.
3.2. Diagnostic criteria for CIUE
The inclusion and exclusion criteria for the collection of cases in
the included studies are summarized in Table 2. Some groups did
not clearly state their inclusion and/or exclusion criteria for
selecting cases.
3.2.1. Inclusion criteria for the selection of cases
The only inclusion criterion used in all 18 studies was the
presence of an infiltrate in the intervillous space. In 67% of the
studies (12 publications) CIUE was defined explicitly as the pres-
ence of mononuclear cells in the intervillous space
[1,2,6,7,9,10,16e18,31,33e35]. Nine groups (50%) mentioned that
the infiltrate should contain histiocytes [3,6e8,18,29,31,32,34,35].
Table 1
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32 28 32 31 Placentas of complicated and
uncomplicated pregnancies with
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64 We defined cases as placentas with
massive chronic intervillositis (18)
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24 23 154 143 Villitis of unknown etiology (78),









18 studies were included in this systematic review. One study had a prospective study design. These studies describe 350 pregnancies with CIUE in 291women. Several control
groups were used in case-control studies. Data per patient were provided in eight studies. Abbreviations; Re, Retrospective; CC, Case-control study; CS, Case series; Pr,
Prospective.
M. Bos et al. / Placenta 61 (2018) 80e88 83
Table 2



































































þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ 100
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Trophoblastic
necrosis
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Villitis þ þ þ þ þ 28
Chorioamnionitis þ þ þ 17
Cytomegalovirus
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Several inclusion criteria and exclusion criteria were used for the selection of patients. “þ” in the table indicates that the study used this particular inclusion criterion or exclusion criterion. The only uniform inclusion criterion












M. Bos et al. / Placenta 61 (2018) 80e88 85Seven groups (39%) stated that only patients with a massive,
diffuse, or widespread infiltrate in the intervillous space should be
included [1,3,8,18,30,33,34]. Four and three groups used the pres-
ence of fibrin deposits and trophoblastic necrosis, respectively, as
an inclusion criterion [1,2,9,16,17]. Finally, three groups stated that
the infiltrate should be maternal in origin to be defined as CIUE
[10,34,35].
3.2.2. Exclusion criteria for the selection of cases
Eleven groups (61%) specifically excluded patients with an in-
fectious cause of CIUE [1,2,6,8,9,17,18,30,33,34]; four groups
excluded patients with malaria or cytomegalovirus infection
[2,18,30,35], three groups excluded patients with chorioamnionitis
[8,17,33], and four groups excluded patients with other infectious
diseases [1,6,9,34]. The largest discrepancy with respect to exclu-
sion criteriawas regarding the co-occurrence of chronic villitis with
intervillositis; five groups excluded cases with chronic villitis
[3,7,9,16,29], whereas one group explicitly stated that they included
only cases with focal chronic villitis [2]. Marchaudon et al. reported
that they excluded cases with intervillositis associated with other
placental lesions [31].
3.3. Histopathological findings
Supplemental Tables 1 and 2 provide an overview of the histo-
logical findings and the composition of the cell infiltrates. One
group found fibrin deposits in 18% of cases [17]; another group
found fibrin deposits in 100% of cases [1]. Four groups used the
presence of perivillous fibrin deposits as an inclusion criterion
[1,2,9,16]; in contrast, groups that also mentioned the presence of
fibrin deposits did not use this as an inclusion criterion [3,17,29,30].
The presence of fibrin was reported in different grades from low to
diffuse [3,16,31]. Trophoblast necrosis and erosion were noted by
Capuani et al. [9], and Labarrere et al. reported a prevalence of 100%Table 3
Maternal characteristics and obstetrical features.
Study provided data per
patient




þ 30.5 (7.4) [21e42]
Jacques and Qureshi,
1993 [16].
þ 29.0 (4.6) [23e37]
Boyd and Redline, 2000
[3].
29.8 (6.2) [20e43]
Rota et al., 2006 [17]. 30.1
Parant et al., 2009 [2]. þ 30 [24e39]
Traeder et al., 2010
[29].





Capuani et al., 2013 [9]. þ 30 (5.4)
Freitag et al., 2013 [30]. þ [25e35]
Reus et al., 2013 [10]. 31.8 (4.9) [22e45]
Labarrere et al., 2014
[8].
median, 28 [21e42]
Bendon et al., 2015 [7]. þ
Labarrere et al., 2015
[33].
median, 29 [18e42]
Mekinian et al., 2015
[18].
34 (5)
Revaux et al., 2015 [34]. median, 30 [22e40]
Nowak C et al., 2016
[6].
Sabra et al., 2016 [35]. þ 34.8 (2.4) [32e39]
The maternal characteristics of the included patients with an intervillous infiltrate and the
studies. Two publications did not provide information regarding maternal characteristicin their original paper on massive chronic intervillositis [1]. The co-
occurrence of villitis was observed in 25e76% of cases with CIUE
[1,2,6,17,18,29,33]; however, the presence of villitis was also used as
an exclusion criterion by six groups [2,3,7,9,16,29]. Two groups
studied combined lesions with CIUE and villitis [6,7].
Five groups extensively studied the composition of the inter-
villous infiltrates [3,9,29,30,33]. The majority of cells (approxi-
mately 80%) were positive for CD68; moreover, Boyd et al. [3] found
that approximately 30e40% of these CD68 þ cells expressedMRP14.
The marker MRP14 is also known as S100A9 [36], this marker is
expressed by an activated immature monocyte/macrophage subset
[37]. T cells (5e24%) and subtypes of T cells were also observed in
the infiltrate, including (CD8þ) cytotoxic T cells (7.7e17.1% of cells),
(CD4þ) T helper cells (5.1e14.4% of cells) [9,30,33], and regulatory T
cells (approximately 5% of cells) [9]. Finally, one group reported that
4% of the cells in the infiltrate were B cells (see Supplemental
Table 2) [9].
3.4. Maternal characteristics and obstetrical features
Eight of the publications reported the maternal characteristics,
obstetrical features, and pregnancy outcomes per patient
[1,2,7,9,16,29,30,35]. The maternal characteristics and obstetrical
features varied widely among the studies (Table 3). Maternal age
ranged from 18 years to 45 years, gravidity ranged from 1 to 11, and
parity ranged from 0 to 8. The presence of CIUE was reported in
placenta samples from all three trimesters. Several conditions and
factors appeared to be associated with CIUE, including autoimmune
disease, preeclampsia, assisted reproduction, and smoking
(Supplemental Table 3) [3,8,10,16e18,29e31,33,34].
3.5. Pregnancy outcome




Mean gestational age, days (SD, days)
[range, days]
3.5 [1e5] 2 [1e5] 265 (14) [238e280]
3.5 [3e11] 1 [1e7] 191 (41) [140e266]
5 [1e9]
2.5 [1e10] 1 [0e6] 199 (65) [56e284]
1.5 [1e4] 1 [1e2] 218 (22) [189e249]
3 [1e9] 0 [0e4] 188 (54) [77e273]
[1e3] [0e1] [134e225]
mean (SD), 4.5 (3.1)
[1e13]
mean (SD), 2.3 (1.9)
[0e8]
181 (72) [56e283]
1 [0e4] 1 [0e4] median, 266 [238e280]
2.5 [1e11] 224 (50) [91e280]
2 [1e6] 1 [0e4] median, 266 [238e287]
3 [2e6] 1 [0e1] 94 (62) [56e231]
obstetrical features of pregnancies complicated with CIUE varied widely among the
s. Abbreviations; SD, standard deviation.
M. Bos et al. / Placenta 61 (2018) 80e8886with CIUE is provided in Supplemental Table 4. The overall incidence
rates of each pregnancy outcome are shown in Table 4. Miscarriage
was reported in 62 out of 256 (24.2%) pregnancies. This might be
underestimated, as some groups included only pregnancies that
resulted in a live birth [8,33]. Approximately 50% of miscarriages
were late miscarriages (24 out of 52); in seven publications the
majority of documented miscarriages were late miscarriages
[2,6,7,9,16,30,32]. However, in two studies with a relatively high
incidence of miscarriage, 70e82% of documented miscarriages were
early miscarriages [3,31]. Impaired fetal growth was reported for
nearly 65% of pregnancies. Specifically, 63 out of 88 fetuses had
intrauterine growth restriction, and 40 out of 66 fetuses were small
for their gestational age. The number of fetuses with impaired
growth was slightly underestimated, as some groups defined
impaired fetal growth as either an estimated fetal weight or birth
weight in the bottom 3rd percentile of reference curves [6,31]. Only
59 out of 182 pregnancies (32.4%), which provided sufficient infor-
mation on gestational age at birth, resulted in a term birth; this
percentage increased slightly to 38.1%when earlymiscarriages were
excluded. Fifty-five out of 190 documented pregnancies ended in
stillbirth, and six neonatal deaths were documented [16]. Among
the pregnancies with CIUE, 135 resulted in live-born infants (54.9%);
this percentage increased to 59.4% when early miscarriages were
excluded. The rate of recurrence among 199 women was 25.1% and
ranged from 4.2% to 100%. One prospective study reported a recur-
rence rate of 33.3% among 24 women with CIUE [18].
4. Discussion
Our objective was to investigate the definitions, inclusion
criteria, and exclusion criteria in studies regarding CIUE published
since 1987. In addition, we provided an overview of the histological
findings, maternal characteristics, obstetric features, and reported
outcome of cases in the included studies. We found that studies
regarding CIUE use different inclusion criteria and exclusion criteria
for selecting cases with CIUE, or they used different definitions.
Indeed, the only criterion used by all groups was the presence of an
intervillous infiltrate in the placenta. Despite this wide variation
among publications, all publications underline that CIUE is a
serious condition characterized by adverse fetal outcome, including
high rates of miscarriage, impaired growth, reduced term births,
and a reduced live birth rate. In addition, the relatively high rate of
recurrence (25.1% of patients) underscores the high clinical rele-
vance of CIUE.
4.1. Strengths and limitations of this study
This study provides an accurate overview of publications
describing the lesion CIUE. Furthermore, this review is the first step
towards standardized criteria for diagnosing CIUE. Limitations of
this study are the limited number of included patients andTable 4







Number of studies 15 7 7 7 11 11
Total number of pregnancies
or patients
256 52 88 66 182 155
Number of pregnancies or
patients with outcome
62 24 63 40 59 59
% 24.2 46.2 71.6 60.6 32.4 38.1
Number of studies represents the number of publications that reported the respective out
in those studies; number of pregnancies or patients with outcome represents the number
patients with the indicated outcome divided by the number of pregnancies or patients, e
small for gestational age.incomplete patient characteristics and obstetric characteristics,
caused by the study design and reporting of included studies. For
instance, some groups provided limited information regarding
pregnancy outcome, used different criteria for pregnancy outcome,
or reported the outcome of pregnancies with an intervillous infil-
trate together with pregnancies without CIUE.
4.2. Limitations of the included studies
We found that the definitions used differed among publications;
patient characteristics, histopathological findings, and pregnancy
outcomes differed between studies, giving rise to the question
whether CIUE is a self-contained entity.
With one exception [18], all the studies included in our review
were retrospective studies. A retrospective study may favor the se-
lection of patients with a severe and/or suspicious case history,
thereby leading to selection bias. Furthermore, most of these cases
were selected based on a previous diagnosis by a pathologist. Pa-
thologists who do not specialize in examining placentas can expe-
rience difficulties in properly recognizing the lesion and therefore
tend to diagnose the more severe cases [32]. On the other hand,
pathologists who are familiar with CIUE may diagnose less suspi-
cious cases. Kramer et al. reported high levels of both intra-observer
and inter-observer agreement with respect to the histological fea-
tures of acute placental inflammation [38]; however, such results
can be generalized only to experienced placental pathologists [38].
Moreover, a diagnosis of CIUE is based on a process of elimination,
most groups attempted to exclude an underlying infection. How-
ever, due to the retrospective study design, adequate patient ma-
terials (e.g., blood samples, frozen placental specimens, etc.) may not
be available. This may lead to incorrectly diagnosing a case as well.
On the other hand, several groups reported a substantial risk of
recurrence of CIUE after a reported lesion [3,7,9,18], and the
outcome in patients with CIUE is generally less favorable compared
with patients with placentas without any lesions, with villitis of
unknown etiology, or with a combined lesion of villitis and inter-
villositis [1,6]. The recurrence of the infiltrates and adverse out-
comes in patients with CIUE is in favor of CIUE being a self-
contained entity. Furthermore, there appears to be an association
between CIUE and autoimmune disease and it is striking that ten of
the 18 publications mentioned that some of the included patients
had preeclampsia (see Supplemental Table 3). Preeclampsia is a
pregnancy-related syndrome characterized by impaired placental
function, immune-dysregulation and subsequent maternal endo-
thelial dysfunction [39]. These associations might provide some
insights in a possible immunological etiology of CIUE. However, due
to case selection, it is not possible to draw definitive conclusions. To
determine whether CIUE is truly a self-contained entity and to
reveal the etiology of CIUE, the presence of selection bias should be








in a living child
Recurrence
13 2 13 11 10
190 9 246 180 199
55 6 135 107 50
28.9 60.0 54.9 59.4 25.1
come; number of pregnancies or patients represents the number of patients included
of patients with the indicated outcome; % represents the of number of pregnancies or
xpressed as a percentage. Abbreviations; IUGR, intrauterine growth restriction; SGA,
M. Bos et al. / Placenta 61 (2018) 80e88 874.3. Towards standardized criteria for the diagnosis of chronic
intervillositis of unknown etiology
Based on our thorough analysis of articles on CIUE published
from 1987 through February 2017, we propose standardized criteria
for diagnosing CIUE.Criteria for the diagnosis of chronic intervillositis of un-
known etiology
Inclusion criteria
Criterion I: An infiltrate is present in the intervillous space.
Criterion II: Approximately 80% of the mononuclear-cells in
the intervillous space are CD68-positive cells.
Criterion III: The intervillous space should be occupied by
an infiltrate for 5% or more.
Exclusion criterion
Criterion IV: Caseswith clinical or histopathological signs of
infection should be excluded.4.3.1. Characteristics of the intervillous infiltrates
The most important diagnostic criterion is the presence of an
intervillous infiltrate containing predominantly mononuclear cells
(Criterion I). Several groups suggested that these mononuclear cells
in the intervillous space have a histiocytic phenotype
[3,9,13,18,29e32,35]. The presence of histiocytes in the intervillous
space can be confirmed with immunohistochemistry [32]. In five
publications is suggested that approximately 80% of the cells in the
intervillous infiltrates should be CD68þ-cells (Supplemental
Table 2) [3,9,29,30,33] (Criterion II), and the number of CD68þ-
cells in the intervillous space should be four-times higher than in
normal placentas [32]. 5% or more of the placental intervillous
space should be occupied by intervillous infiltrates [29] (Criterion
III). The intervillous infiltrates should be present in at least two out
of three full-thickness sections of macroscopic normal-appearing
placenta parenchyma in third trimester placentas [40]. The
required number of sections might not be available in first and
second trimester samples, in these cases at least 5% or more of the
placental invervillous space of the sampled specimen should
contain intervillous infiltrates. The presence of a widespread infil-
trate was used as an inclusion criterion in seven studies in our re-
view and the severity of the infiltrate may be correlated with
pregnancy outcome [2]. Severe intrauterine growth restriction and
intrauterine fetal death were observed in cases with a severe
infiltrate, and the perinatal prognosis was better in cases with a
moderate infiltrate [2]. However, it is also reported that the inter-
villous infiltrate is less severe in cases complicated with intra-
uterine fetal death [31]. The severity of the infiltrate in relation to
clinical outcomes is an interesting topic for more in-depth research.
In three studies is suggested that the intervillous infiltrate should
be of maternal origin [10,34,35], and this was confirmed in one
study [29]. The maternal origin of the infiltrate is plausible, based
on its location, but it is trivial for diagnosis criteria.
4.3.2. Co-occurring histopathological findings
The co-occurrence of different histopathological findings is not
consistent in reported placentas with CIUE. This could be the result
of chosen inclusion criteria in the various studies. The biggest
discrepancy between studies is in the inclusion of cases with
chronic villitis. Three different approaches were observed: pla-
centas with co-occurring villitis were excluded [3,7,9,16,29], onlyplacentas with focal villitis were included [2] or placentas with
CIUE and villitis were studied [6,7]. Limited evidence is available to
exclude cases with villitis. Therefore, cases with CIUE and co-
occurring villitis should not be excluded. Presence of fibrin,
trophoblastic necrosis, and/or atherosis should also not be required
for a diagnosis of CIUE, nor should it rule out the presence of CIUE.
Nevertheless, co-occurring histopathological findings in CIUE could
provide important insight into the pathophysiology of CIUE and
further studies should comprehensively describe the co-occurring
histopathological lesions in cases with CIUE.
4.3.3. Excluding infectious causes
Cases with clinical or histopathological signs of infection should
be excluded (Criterion IV). In the event of an unfavorable pregnancy
outcome (e.g., miscarriage, restricted fetal growth, preterm birth, or
stillbirth), most women are screened for the presence of a TORCH
infection (toxoplasmosis, treponema pallidum, rubella, cytomega-
lovirus, herpes virus, and other infections, including varicella,
parvovirus B19, HIV, and enteroviruses) [41]. TORCH infections are
a major contributor to prenatal, perinatal, and postnatal morbidity
and mortality, and should therefore be excluded in the case of CIUE
[41]. Furthermore, one should discriminate between a polymorphic
infiltrate and a monomorphic infiltrate; a polymorphic infiltrate
containing neutrophils and leukocytes is indicative for acute
inflammation. Cases with a predominant polymorphic infiltrate
should be excluded. A pathologists' finding of evidence of infection
is usually scarce; therefore, infectious causes should preferably be
excluded based on clinical findings.
4.3.4. Maternal characteristics and obstetric features
In this review, we found that CIUE is reported in mothers of
various ages and with a variety of obstetrical histories. Thus, neither
the maternal characteristics nor the medical history should neces-
sarily serve as either an inclusion or exclusion criterion. A prospective
study should be conducted in order to demonstrate a clear associa-
tion between the intervillous infiltrate and pregnancy outcome
before an adverse pregnancy outcome can be used as an inclusion
criterion. Since, associations found between intervillous infiltrates
and pregnancy outcome might have been caused by selection bias.
Associations between increased levels of maternal serum alkaline
phosphatase and CIUE might provide an interesting new diagnostic
approach, which should be investigated further [31,42,43].
4.3.5. Future validation
Although consensus does not yet exist regarding these diag-
nostic criteria, our results set the stage for establishing standard-
ized criteria for diagnosing CIUE. The next step towards
understanding the etiology of CIUE is to determine the precise
criteria by performing a Delphi study [44]. Thereafter, these criteria
should be validated in several patient populations; in a first step
towards validation, the pathologists who contributed to the
Amsterdam Placental Workshop Group Consensus Statement [40]
could assess our proposed diagnostic criteria and examine the
cases included in this review. Future studies regarding CIUE should
attempt to determine the full spectrum of the syndrome.
5. Conclusions
Here, we propose a set of standardized diagnostic criteria for
CIUE, a serious pregnancy complication frequently associated with
miscarriage, impaired fetal growth, preterm birth, and a live birth
rate of only 54.9%. The relatively high rate of recurrence (25.1%) in
subsequent pregnancies and the accompanying pregnancy com-
plications underscore the high clinical relevance of CIUE and the
need for further in-depth research.
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